SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-029398
Filing Date
2022-08-15
Accepted
2022-08-15 08:02:09
Documents
68
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q ljpc-10q_20220630.htm   iXBRL 10-Q 1843442
2 EX-31.1 ljpc-ex311_7.htm EX-31.1 18460
3 EX-31.2 ljpc-ex312_8.htm EX-31.2 18393
4 EX-32.1 ljpc-ex321_6.htm EX-32.1 15862
5 GRAPHIC gea0okol1cvk000001.jpg GRAPHIC 74645
  Complete submission text file 0001564590-22-029398.txt   6795850

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ljpc-20220630.xsd EX-101.SCH 58260
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ljpc-20220630_cal.xml EX-101.CAL 51251
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ljpc-20220630_def.xml EX-101.DEF 186363
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE ljpc-20220630_lab.xml EX-101.LAB 422469
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ljpc-20220630_pre.xml EX-101.PRE 311630
62 EXTRACTED XBRL INSTANCE DOCUMENT ljpc-10q_20220630_htm.xml XML 961510
Mailing Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451
Business Address 201 JONES ROAD, SUITE 400 WALTHAM MA 02451 617-715-3600
LA JOLLA PHARMACEUTICAL CO (Filer) CIK: 0000920465 (see all company filings)

IRS No.: 330361285 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36282 | Film No.: 221162440
SIC: 2836 Biological Products, (No Diagnostic Substances)